These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9883616)

  • 1. [The adverse reactions of anti-tuberculosis drugs and its management].
    Wada M
    Nihon Rinsho; 1998 Dec; 56(12):3091-5. PubMed ID: 9883616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.
    Durand F; Jebrak G; Pessayre D; Fournier M; Bernuau J
    Drug Saf; 1996 Dec; 15(6):394-405. PubMed ID: 8968694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Management of adverse effects with antituberculosis chemotherapy].
    Tsuyuguchi K; Wada M
    Kekkaku; 2011 Feb; 86(2):87-99. PubMed ID: 21404653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse drug reactions in TB therapy: risks and recommendations.
    Yoshikawa TT; Nagami PH
    Geriatrics; 1982 Jul; 37(7):61-8. PubMed ID: 7084671
    [No Abstract]   [Full Text] [Related]  

  • 6. [Adverse effects of antitubercular drugs: epidemiology, mechanisms, and patient management].
    Aouam K; Chaabane A; Loussaïef C; Ben Romdhane F; Boughattas NA; Chakroun M
    Med Mal Infect; 2007 May; 37(5):253-61. PubMed ID: 17336011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.
    Tostmann A; Boeree MJ; Aarnoutse RE; de Lange WC; van der Ven AJ; Dekhuijzen R
    J Gastroenterol Hepatol; 2008 Feb; 23(2):192-202. PubMed ID: 17995946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report.
    Saigal S; Agarwal SR; Nandeesh HP; Sarin SK
    J Gastroenterol Hepatol; 2001 Sep; 16(9):1028-32. PubMed ID: 11595068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-tuberculosis chemotherapy and management of adverse reactions].
    Kuwabara K
    Nihon Rinsho; 2011 Aug; 69(8):1389-93. PubMed ID: 21838035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The management of anti-tuberculosis drug-induced hepatotoxicity.
    Tahaoğlu K; Ataç G; Sevim T; Tärün T; Yazicioğlu O; Horzum G; Gemci I; Ongel A; Kapakli N; Aksoy E
    Int J Tuberc Lung Dis; 2001 Jan; 5(1):65-9. PubMed ID: 11263519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs.
    Schreiber J; Zissel G; Greinert U; Schlaak M; Müller-Quernheim J
    Eur J Med Res; 1999 Feb; 4(2):67-71. PubMed ID: 10066642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A case of tuberculous meningitis complicated with multiple drug hypersensitivity to antituberculosis agents].
    Arai M
    Rinsho Shinkeigaku; 2015; 55(2):123-5. PubMed ID: 25746078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
    de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
    Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatotoxicity to different antituberculosis drug combinations.
    Aziz S; Agha F; Hassan R; Fairoz SA; Hassan K
    J Pak Med Assoc; 1990 Dec; 40(12):290-4. PubMed ID: 2126569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity.
    Fernández-Villar A; Sopeña B; Fernández-Villar J; Vázquez-Gallardo R; Ulloa F; Leiro V; Mosteiro M; Piñeiro L
    Int J Tuberc Lung Dis; 2004 Dec; 8(12):1499-505. PubMed ID: 15636498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular side effects of antitubercular drugs - a focus on prevention, early detection and management.
    Kokkada SB; Barthakur R; Natarajan M; Palaian S; Chhetri AK; Mishra P
    Kathmandu Univ Med J (KUMJ); 2005; 3(4):438-41. PubMed ID: 16449853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse drug reactions and outcome of elderly patients on antituberculosis chemotherapy with and without rifampicin.
    Chan CH; Or KK; Cheung W; Woo J
    J Med; 1995; 26(1-2):43-52. PubMed ID: 7561530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Survey of anti-tuberculosis drug-induced severe liver injury in Japan].
    Shigeto E;
    Kekkaku; 2007 May; 82(5):467-73. PubMed ID: 17564126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between steady-state plasma concentration of antituberculous drugs and age, inclusion of rifampicin in the treatment regimen, adverse drug reactions and other clinical parameters.
    Woo J; Chan C; Chan R; Cheung W; Or K; Chan K
    J Med; 1995; 26(5-6):279-94. PubMed ID: 8721904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Leukopenia due to anti-tuberculous chemotherapy including rifampicin and isoniazid].
    Nagayama N; Shishido Y; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Komatsu H; Yotsumoto H
    Kekkaku; 2004 May; 79(5):341-8. PubMed ID: 15211874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.